Department of Neurology, Regensburg University Hospital, Regensburg, Germany.
Department of Neurology, Donau-Isar-Klinikum Deggendorf, Deggendorf, Germany.
J Neurooncol. 2023 Aug;164(1):249-256. doi: 10.1007/s11060-023-04403-6. Epub 2023 Aug 2.
Patients with glioblastoma are exposed to severe symptoms and organs failures (e.g., coma or acute respiratory failure), that may require intensive care unit (ICU) admission and invasive mechanical ventilation (IMV). However, only limited data are available concerning the prognosis of patients with glioblastoma receiving IMV. We sought to describe the reasons for ICU admission, and outcomes of patients with glioblastoma requiring IMV for unplanned critical complications.
In this retrospective analysis, four certified interdisciplinary brain tumor centers performed a retrospective review of their electronic data systems. All patients with glioblastoma admitted to an in-house ICU and receiving IMV between January 2015 and December 2019 were included. Clinical and prognostic factors as well as relevant outcome parameters were evaluated by group comparisons and Kaplan Meier survival curves.
We identified 33 glioblastoma patients with a duration of IMV of 9.2 ± 9.4 days. Main reasons for ICU admission were infection (n = 12; 34.3%) including 3 cases of Pneumocystis jirovecii pneumonia, status epilepticus (31.4%) and elevated intracranial pressure (22.9%). In-hospital mortality reached 60.6%. Younger age, low number of IMV days, better Karnofsky Performance Status Scale before admission and elevated intracranial pressure as cause of ICU admission were associated with positive prognostic outcome.
We conclude that less than 50% of patients with glioblastoma have a favorable short-term outcome when unplanned ICU treatment with IMV is required. Our data mandate a careful therapy guidance and frequent reassessment of goals during ICU stay.
胶质母细胞瘤患者会出现严重的症状和器官衰竭(例如昏迷或急性呼吸衰竭),这可能需要入住重症监护病房(ICU)并进行有创机械通气(IMV)。然而,关于接受 IMV 的胶质母细胞瘤患者的预后仅有有限的数据。我们旨在描述因计划外危急并发症而需要接受 IMV 的胶质母细胞瘤患者入住 ICU 的原因和结局。
在这项回顾性分析中,四个认证的多学科脑肿瘤中心对其电子数据系统进行了回顾性审查。所有在 2015 年 1 月至 2019 年 12 月期间入住内部 ICU 并接受 IMV 的胶质母细胞瘤患者均被纳入研究。通过组间比较和 Kaplan-Meier 生存曲线评估了临床和预后因素以及相关的预后参数。
我们共确定了 33 名接受 IMV 治疗的胶质母细胞瘤患者,其 IMV 持续时间为 9.2±9.4 天。入住 ICU 的主要原因是感染(n=12;34.3%),包括 3 例卡氏肺孢子虫肺炎、癫痫持续状态(31.4%)和颅内压升高(22.9%)。住院死亡率为 60.6%。年龄较小、IMV 天数较少、入院前 Karnofsky 表现状态评分较好以及颅内压升高作为 ICU 入院的原因与预后良好相关。
我们得出结论,当需要计划外 ICU 治疗并接受 IMV 治疗时,不到 50%的胶质母细胞瘤患者具有良好的短期预后。我们的数据需要仔细的治疗指导,并在 ICU 期间频繁重新评估治疗目标。